Ensign Peak Advisors
PRCT icon

Ensign Peak Advisors’s Procept Biorobotics PRCT Stock Holding History

Ensign Peak Advisors’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97.4K Buy
4,315
+200
+5% +$5.01K ﹤0.01% 1622
2026
Q1 		$103K Hold
4,115
– – ﹤0.01% 1562
2025
Q4 		$129K Sell
4,115
-9,650
-70% -$320K ﹤0.01% 1497
2025
Q3 		$491K Sell
13,765
-400
-3% -$18.3K ﹤0.01% 1397
2025
Q2 		$816K Hold
14,165
– – ﹤0.01% 1366
2025
Q1 		$825K Hold
14,165
– – ﹤0.01% 1354
2024
Q4 		$1.14M Buy
14,165
+150
+1% +$12.8K ﹤0.01% 1240
2024
Q3 		$1.12M Hold
14,015
– – ﹤0.01% 1252
2024
Q2 		$856K Buy
14,015
+4,400
+46% +$262K ﹤0.01% 1382
2024
Q1 		$475K Buy
+9,615
New +$458K ﹤0.01% 1634
2022
Q4 		– Sell
-3,690
Closed -$153K – 2111
2022
Q3 		$153K Buy
+3,690
New +$147K ﹤0.01% 1969

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ensign Peak Advisors's PRCT Position: Q2 2026 in Review

Ensign Peak Advisors increased its Procept Biorobotics (PRCT) stake by 4.9% in Q2 2026, buying an estimated $5.01K and bringing the position to 4,315 shares worth $97.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1622.

Ensign Peak Advisors first reported a position in PRCT in Q3 2022 and has held it in 11 quarters since. The position peaked at $1.14M in Q4 2024. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Ensign Peak Advisors held 4,315 shares of Procept Biorobotics worth $97.4K as of Q2 2026.
  • Ensign Peak Advisors bought 200 Procept Biorobotics shares in Q2 2026, an estimated $5.01K.
  • Procept Biorobotics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1622 holding.
  • Ensign Peak Advisors first reported a position in Procept Biorobotics in Q3 2022 and has held it in 11 quarters since.
  • Ensign Peak Advisors's Procept Biorobotics position peaked at $1.14M in Q4 2024.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.